DelveInsight’s “IL-23 Inhibitors Target Population, Competitive Landscape, and Market Forecast–2034” report delivers an in-depth understanding of the IL-23, historical and Competitive Landscape as well as the IL-23 inhibitor market trends in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover which indication is expected to grab the major interleukin-23 inhibitors market share @ https://www.delveinsight.com/sample-request/interleukin-23-inhibitors-market
Key Takeaways from the Interleukin-23 Inhibitors Market Report
- In March 2025, Johnson & Johnson announced new Icotrokinra data from its comprehensive Phase III clinical program and the start of the first-ever head-to-head study in plaque psoriasis seeking to demonstrate the superiority of an oral pill, Icotrokinra, compared to an injectable biologic, ustekinumab.
- In April 2025, Johnson & Johnson released new Icotrokinra data from a subgroup analysis of ICONIC-LEAD in moderate-to-severe plaque psoriasis to assess the efficacy and safety of systemic therapy in adolescents and adults simultaneously. These data were presented at the 2025 WCPD annual meeting.
- In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida.
- In March 2025, SFA Therapeutics announced positive data from its Phase Ib clinical trial of SFA-002, an oral treatment for mild-to-moderate chronic plaque psoriasis. The study met its primary endpoint of safety, with no TRAEs or toxicities observed during the treatment period, and no rebound effects were noted.
- Among the location-specific contributions, scalp psoriasis had the highest occurrence of cases from 4,811,200 in 2024 in the US.
- Psoriasis is predominantly observed in adults, accounting for approximately 97% of all cases in the 7MM in 2024, also among the type-specific cases of psoriasis, erythrodermic psoriasis accounted for the least number of cases in the 7MM.
- Among the EU4 countries, Germany accounted for the largest number of diagnosed prevalent Crohn’s disease cases followed by the UK, whereas Spain accounted for the lowest number of cases in 2024.
- It has been observed that the highest number of ulcerative colitis affected people was found in 18─44 years of age group.
- Assessments show that based on the severity, ulcerative colitis is classified into two categories i.e. mild and moderate-to-severe. Approximately ~60% of cases of ulcerative colitis belong to the moderate-to-severe category, whereas ~40% of cases are mild.
- In EU4 and the UK, Germany accounted for the highest number of Parkinson’s disease treated cases with approximately 501,500 in 2024.
- The leading Interleukin-23 Inhibitors Companies include Eli Lilly, AbbVie, Boehringer Ingelheim, Sun Pharmaceuticals, Almirall, Janssen Biotech (Johnson & Johnson), Johnson & Johnson, Protagonist Therapeutics, SFA Therapeutics, and others.
- Promising Interleukin-23 Inhibitors Pipeline Therapies include Icotrokinra (JNJ-77242113), SFA-002, Bezisterim (NE3107), and others.
Discover which indication is expected to grab the major interleukin-23 inhibitors market share @ Interleukin-23 Inhibitors Market Report
Interleukin-23 Inhibitors Marketed Drugs
- SKYRIZI (risankizumab-rzaa): AbbVie/Boehringer Ingelheim
SKYRIZI is an IL-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. It is a biologic therapy approved to treat the diseases in North America, the European Union, and Japan. In psoriatic disease (psoriasis or psoriatic arthritis), SKYRIZI is administered as a quarterly Subcutaneous (SC) injection following two induction doses. SKYRIZI is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. SKYRIZI inhibits the release of proinflammatory cytokines and chemokines.
- ILUMYA/ILUMETRI (tildrakizumab-asmn): Sun Pharma
ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of proinflammatory cytokines and chemokines. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.
Interleukin-23 Inhibitors Emerging Drugs
- Icotrokinra (JNJ-77242113): Johnson & Johnson Innovative Medicine/Protagonist Therapeutics
Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque psoriasis and offers potential in other IL-23-mediated diseases. Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrates potent, selective inhibition of IL-23 signaling in human T cells. The license and collaboration agreement established between Protagonist Therapeutics and Johnson & Johnson company in 2017 enabled the companies to work together to discover and develop next-generation compounds that ultimately led to icotrokinra. As per Johnson & Johnson’s earning presentation for the first quarter of 2025, the company anticipates potential clinical data of Phase III ICONIC-LEAD, ICONIC-Advance 1/2, and ICONIC-TOTAL trials in 2025.
- SFA-002: SFA Therapeutics
SFA-002 is a first-in-class oral immunomodulator that operates through multiple cellular pathways to treat autoimmune conditions, with an initial focus on mild-to-moderate chronic plaque psoriasis. Unlike current therapies that target single pathways through immunosuppression, SFA-002 works by simultaneously down-regulating multiple proinflammatory cytokines, including TNF-α, IL-23, IL-10, IL-12, IL-17, and INF-γ, while modulating autoimmune responses. This oral compound has demonstrated promising efficacy in clinical trials, with an excellent safety profile and no observed adverse events. Currently, in Phase Ib clinical development, SFA-002 represents a potential paradigm shift in autoimmune disease treatment, offering a multi-targeted approach that could provide patients with a safer, more accessible alternative to current injectable immunosuppressive therapies.
Learn more about the interleukin-23 inhibitors @ Interleukin-23 Inhibitors Drugs Analysis
Interleukin-23 Inhibitors Market Outlook
The IL-23 inhibitor class has become a cornerstone in the treatment of chronic immune-mediated inflammatory diseases, particularly plaque psoriasis, Crohn’s disease, and ulcerative colitis, due to its targeted mechanism and favorable long-term safety profile. IL-23, a pro-inflammatory cytokine, plays a central role in the differentiation and maintenance of Th17 cells, which are key drivers of inflammation in several autoimmune disorders. Since the approval of the first IL-23 inhibitor in 2017, the market has grown steadily, driven by increasing biologic adoption, improved disease control, and the development of novel delivery platforms. Currently, the IL-23 inhibitor market is led by TREMFYA from Janssen Biotech, the agent approved in 2017 for psoriasis, followed by ILUMYA from Sun Pharma/Almirall in 2018, SKYRIZI from AbbVie and Boehringer Ingelheim in 2019, and most recently OMVOH from Eli Lilly, which gained FDA approval in 2023 for ulcerative colitis. These agents, administered via subcutaneous or intravenous injection, have demonstrated durable efficacy, minimal immunosuppression, and convenient dosing schedules, making them preferred options in both dermatology and gastroenterology.
Interleukin-23 Inhibitors Market Dynamics
The interleukin-23 inhibitors market has seen significant growth in recent years, driven primarily by the increasing global burden of autoimmune diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis. Targeted therapies that inhibit the IL-23 pathway, particularly those that block the p19 subunit, have demonstrated superior efficacy and safety profiles compared to older biologics, thus gaining rapid adoption among healthcare providers and patients. A key driver of this market is the successful commercialization of biologics such as SKYRIZI, TREMFYA, ILUMYA/ILUMETRI, and the more recent OMVOH, which specifically target the IL-23 p19 subunit. These agents offer improved disease control, convenient dosing schedules, and lower immunogenicity, which enhances long-term adherence. Additionally, their favorable safety profiles relative to older tumor necrosis factor (TNF) inhibitors have made them attractive options, particularly for patients who fail to respond to first-line treatments. Continued clinical success, coupled with positive real-world outcomes data, has further solidified their position in treatment algorithms.
To know more about interleukin-23 inhibitors clinical trials, visit @ Interleukin-23 Inhibitors Treatment
Scope of the Interleukin-23 Inhibitors Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Companies- Eli Lilly, AbbVie, Boehringer Ingelheim, Sun Pharmaceuticals, Almirall, Janssen Biotech (Johnson & Johnson), Johnson & Johnson, Protagonist Therapeutics, SFA Therapeutics, and others.
- Interleukin-23 Inhibitors Therapeutic Assessment: Interleukin-23 Inhibitors Current marketed and emerging therapies
- Interleukin-23 Inhibitors Market Dynamics: Attribute Analysis of Emerging Interleukin-23 Inhibitors Drugs
- Interleukin-23 Inhibitors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Interleukin-23 Inhibitors Unmet Needs, KOL’s views, Analyst’s views, Interleukin-23 Inhibitors Market Access and Reimbursement
Discover more about interleukin-23 inhibitors in development @ Interleukin-23 Inhibitors Clinical Trials
Table of Contents
1 Key Insights
2 Report Introduction
3 Executive Summary of Interleukin-23 (IL-23) Inhibitors
4 Key Events
5 Epidemiology and Market Forecast Methodology of IL-23 Inhibitor
6 IL-23 Inhibitor Market Overview at a Glance in the 7MM
7 IL-23 Inhibitor: Background and Overview
8 Target Patient Pool
9 Marketed Products of IL-23 Inhibitor
10 Emerging Therapies of IL-23 Inhibitor
11 IL-23 Inhibitor: Seven Major Market Analysis
12 Market Access and Reimbursement of IL-23 Inhibitors
13 SWOT Analysis of IL-23 Inhibitors
14 KOL Views of IL-23 Inhibitors
15 Unmet Needs of IL-23 Inhibitors
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
